Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Waldenström Macroglobulinemia Progressing on Ibrutinib
NCT04115059Phase 1Terminated
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in Waldenström macroglobulinemia (WM). Primary endpoint: Number of Participants With at Least One Treatment-Emergent Adverse Event at 2 years. Started Nov 2019; status: terminated.
02
Drugs
dasatinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04115059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115059.